That picture is no longer defensible.

Over the past decade, the evidence connecting the gut to the brain has moved from speculative to substantial. We have human studies suggesting that Parkinson's pathology may begin not in the substantia nigra but in the enteric nervous system — the dense web of neurons lining the gut — years before the first tremor appears. We have animal models in which transferring gut microbes from a Parkinson's patient to a healthy mouse produces motor symptoms. We have early human trials in which dietary intervention appears to influence the trajectory of disease. We have a vagus nerve, the longest cranial nerve in the body, carrying signals between gut and brain in both directions, all day, every day, in every patient I see.

And we have a healthcare system that, by and large, has not caught up.

I see this gap up close. A patient with newly diagnosed Parkinson's disease will sit across from me and ask, with the directness of someone who has just been handed a hard diagnosis, "Is there anything I can do?" I can offer medications. I can offer deep brain stimulation in the right patient. I can offer exercise, and I do, every visit, because the evidence for it is overwhelming. And then they ask about food.

What they are usually asking, underneath the question, is whether they have any agency at all. Whether the body that has begun to misbehave can be partnered with rather than simply managed. They are asking whether the next twenty years of their life will happen to them, or whether they get a vote.

The honest answer is that the science is moving faster than the clinic. There are things I can say with confidence. There are more things I can say with cautious optimism. There are things we will know in five years that we do not know today. And there is a world of pseudoscience around all of it — supplements, protocols, twelve-week resets, miracle diets — that makes it harder, not easier, for a patient to find their footing.

The science is moving faster than the clinic. The pseudoscience is moving faster than the science.

So here is what this publication is, and what it isn't.

The Vagus is a field guide — written by a Stanford neurologist who treats movement disorders for a living — to what we are learning about food, the microbiome, and the brain. It will not sell you anything. It will not give you a protocol. It will not promise that the next thing you put on your fork will halt a neurodegenerative disease. What it will do is read the literature carefully, in plain language, with the citations included, and tell you what I think and where I am uncertain. It will share what I am seeing in clinic. And it will write, occasionally and pointedly, about why a healthcare system willing to spend millions of dollars to treat a disease will not pay a dietitian to help prevent it.

I am writing here in a personal capacity. Nothing on this site represents the views of my institution. The work is mine; the citations are public; the goal is clarity.

If you are a patient or a family member trying to make sense of a diagnosis, I am glad you are here. If you are a clinician looking for a translation of a fast-moving literature, I am glad you are here. If you are a researcher, a funder, a journalist, or someone working in food policy, I am glad you are here too. The audience is intentionally mixed, because the work of closing the gap between what the science says and what medicine does requires all of you.

The vagus nerve gets its name from the Latin for wandering. It travels from the brainstem into the chest, around the heart, and down into the gut, branching as it goes. It carries information in both directions. The brain talks to the gut, but the gut, it turns out, has a great deal to say in return.

Most of medicine has spent a long time listening to only one side of that conversation.

This is an attempt to listen to the other.

New essays will arrive most weeks. Sometimes more often, sometimes less. They will be free. There will be no protocols, no supplements, and no twelve-step plans. There will be citations. If that's what you're looking for, you can subscribe below.

Welcome to The Vagus.

If the finding holds, and the replication is already underway, it will reframe a question we have been asking the wrong way for a generation. We have treated dopaminergic loss as a cell-autonomous failure of a vulnerable population of neurons. We have studied mitochondria, lysosomes, α-synuclein. We have not, until very recently, taken seriously the possibility that those neurons live in a chemical environment partly authored by microbes a meter and a half away.

Butyrate is the molecule in question. It is produced when colonic bacteria ferment dietary fiber — the kind of fiber that disappears almost entirely from a Western diet built on refined grains and processed convenience. In the new work, animals raised on a fiber-poor diet showed reduced circulating butyrate, a measurable shift in microglial phenotype, and, downstream, a loss of nigral dopaminergic neurons that no genetic manipulation had been required to induce.

The clinical translation is not yet ours to claim. But the direction of the arrow is hard to ignore: feed the microbes that feed the brain, and the brain appears to be more durable. Starve them, and a population of neurons we cannot replace becomes more vulnerable to insults it would otherwise survive.

I have started, gently, to put a number on it in clinic. Thirty grams of fiber a day. Most of my patients are eating ten.

The questions, in the order I ask them: What did you eat for breakfast yesterday? How often, in a normal week, do you have a bowel movement? When was the last time you cooked a meal from raw ingredients? What does your kitchen look like at four in the afternoon? And — the one that surprises people — who do you eat with?

None of these is a screening instrument. None of them generates a score. They are, instead, a way of finding out whether food is something my patient does or something that happens to them. The distinction is clinically enormous. A patient who cooks has a thousand small levers I can pull. A patient whose dinner arrives in a paper bag has, functionally, none.

The bowel movement question is the one trainees flinch at and the one I have come to consider essential. Constipation is the longest prodrome we have for Parkinson's disease — sometimes more than a decade — and it is also a real-time readout of the system that converts what a patient eats into what their nervous system can use. If transit time is measured in days rather than hours, no dietary intervention is going to do much, and several of the medications we love will make things worse.

The last question, about who they eat with, is not soft. Loneliness predicts cognitive decline more reliably than most of the things I have on the chart. A meal eaten in company is a different physiological event than the same meal eaten alone in front of a screen. I am not sure I can prescribe a dinner companion, but I can at least notice the absence of one.

Medical nutrition therapy, delivered by a registered dietitian, is reimbursed by Medicare in exactly two conditions: diabetes and chronic kidney disease. Not Parkinson's. Not Alzheimer's. Not the long, expensive tail of neurodegenerative disease in which dietary pattern is among the few variables a patient can actually move. The same Medicare program will, without hesitation, pay for the deep brain stimulator and the lifetime of programming visits that follow.

I am not arguing against the stimulator. I am arguing against an accounting system that treats prevention as a luxury and rescue as the standard of care. The economics of this are upside-down in a way that anyone outside healthcare would find difficult to believe.

What was different about this year's summit was the presence, for the first time, of state Medicaid directors who were no longer asking whether food-as-medicine pilots worked, but how to scale them. Several of the better designed programs — produce prescriptions, medically tailored meals — have now generated readmission and cost data strong enough to survive a finance committee. The wall between food and medicine, at the policy level, is finally beginning to crack along its weakest seams.

It is going to take a generation. Reimbursement codes are written slowly and amended more slowly still. But the argument has shifted, and the people writing the checks have started to listen.

Still, the boring answer keeps winning. A diet weighted toward vegetables, legumes, fish, and olive oil — what the epidemiology stubbornly calls the Mediterranean pattern — continues to outperform almost everything else in trials of cognitive aging.

It is not a personality. It is a pattern. The distinction matters.

In a Viewpoint published this month in the Journal of Clinical Investigation, my colleague Robin Voigt at Rush and I make an argument that, until recently, would have been heretical in a movement disorders clinic: that the rising tide of Parkinson's is best understood as an erosion of resilience at the gut, and that the gut — not the substantia nigra — is where prevention has to start.

The frame we propose is convergence. Pesticides, solvents, air pollution, microplastics, ultra-processed food, dietary emulsifiers — none of these on its own explains the curve. Taken together, across decades of low-dose exposure, they do. The gut is the only environmental interface that hosts a metabolically active microbial ecosystem capable of biotransforming what we eat, drink, and breathe into either neuroprotective or neurotoxic metabolites. Even paraquat and trichloroethylene, often inhaled or absorbed dermally, converge on the gut through mucociliary clearance and enterohepatic circulation. The gut is where the exposome becomes biology.

The mechanisms are no longer speculative. Enterobacteriaceae enriched by oxidative stress produce curli, a bacterial amyloid structurally homologous to α-synuclein, which seeds aggregation in the enteric nervous system and primes microglia through TLR2 signaling. Sulfate-reducing bacteria like Desulfovibrio generate pathological excess hydrogen sulfide, inhibiting complex IV. The kynurenine switch shunts tryptophan away from serotonin and toward quinolinic acid. Short-chain fatty acid producers — the boring, butyrate-making workhorses of a healthy microbiome — quietly disappear. By the time the tremor arrives in clinic, this has been happening for fifteen or twenty years.

The therapeutic implication is two-pronged and unglamorous. We have to reduce environmental burden, which is a policy problem more than a pharmacology problem: phase out the worst agrichemicals, regulate dietary emulsifiers, take microplastics seriously. And we have to enhance biological resilience — through fiber, through SCFA-producing synbiotics, through the next generation of precision-engineered strains designed to degrade curli and metabolize xenobiotics.

I want to be honest about what this argument costs. It moves Parkinson's out of the exclusive jurisdiction of neurology and into the shared territory of gastroenterology, environmental health, agriculture, and food policy. It asks regulators to treat exposure with the urgency we already grant to genetic risk. And it asks clinicians like me to ask, at the first visit, what a patient is eating — not as a lifestyle aside but as upstream pathophysiology.

The brain is the eventual target of Parkinson's disease. It is not the origin. If we keep treating it as the origin, we will keep arriving late.

We were trained in an efferent picture of the autonomic nervous system: the brain decides, the periphery executes. The anatomy does not support this picture. Four out of every five fibers in the tenth cranial nerve carry information from the viscera up to the brainstem, where it is integrated, weighted, and forwarded to regions that shape mood, appetite, attention, and — in the long arc — vulnerability to neurodegenerative disease.

When we cut the vagus, in animal models and in the older surgical literature, the rate of subsequent Parkinson's diagnosis falls. That is not a sentence I would have written a decade ago. It is a sentence the data now require.

Last August, a study from Helen Bronte-Stewart's lab at Stanford was published in npj Parkinson's Disease that begins, modestly, to address the absurdity. The instrument is Quantitative Digitography — QDG — a small device that asks the patient to perform a thirty-second alternating finger-tapping task and returns validated, objective metrics of bradykinesia, rigidity, and tremor. Patients did this at home, daily, for thirty days.

The findings were, on first read, straightforward: compliance was excellent, the system was easy to use, and the QDG Mobility Score correlated meaningfully with patients' own reports of activities of daily living. On second read, they are more interesting than that. The device caught motor complexities that a twice-yearly clinic visit would have missed entirely — fluctuations across the day, response to small dose adjustments, the slow drift of disease that reveals itself only when you watch it unfold across weeks.

What this kind of monitoring does, practically, is shrink the dark space between visits. It also raises an honest question for those of us in clinic: how much of what we have been doing has been informed less by data than by inference from a single morning snapshot, taken during the brief best-on window of a day the patient organized around the appointment?

The answer is: more than we like to admit. The promise of remote monitoring is not surveillance. It is humility. It is finally seeing, in something close to continuous time, what the patient has been telling us all along.

Postbiotic, in the technical literature, refers to a preparation of inanimate microorganisms or their components that confers a health benefit on the host. On the supplement shelf, it has come to mean roughly anything a marketing department wants it to mean. The gap is not pedantic. It is the difference between a defined biological agent and a vial of hopeful powder.

Two of the largest prospective cohorts now agree on this within a window of uncertainty I find clinically actionable. Patients who report fewer than three bowel movements per week in midlife carry a meaningfully elevated risk of receiving a Parkinson's diagnosis decades later. The signal survives adjustment for the obvious confounders.

What we do with this information is the harder question. We do not yet have a disease-modifying therapy to offer the asymptomatic constipated fifty-year-old. We do, however, have fiber, hydration, exercise, and a serious conversation about the medications — anticholinergics chief among them — that compound the problem. None of these is a cure. All of them are within reach today.